SITE015-0002

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-02-21

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-04-27 (study day 56); relationship: not assessed; serious criteria: life-threatening

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 77); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 86); relationship: Y

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-06-25 (study day 115); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-28 (study day 118); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 143); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-13 (study day 164); relationship: not assessed

Data queries

No data queries.